Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics Reports Third Quarter 2017 Financial Results
October 26, 2017 4:02 PM EDT-Third Quarter 2017 Revenues Were $135.3 Million, Including $79.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-FDA Breakthrough Therapy Designation Granted for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma; Supplemental Biologics License Application on Track for Submission in the Fourth Quarter of 2017-
-Full Data from ADCETRIS Phase 3 ECHELON-1 Trial Accepted for Presentation at ASH Annual Meeting-
-Pivotal Trial Initiated of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer-
-Conference Call Today at 4:30... More
